Hitchins Megan P, Rickard Sarah, Dhalla Fatima, Fairbrother Una L, de Vries Bert B A, Winter Robin, Pembrey Marcus E, Malcolm Sue
Molecular Embryology Unit, Institute of Child Health and Great Ormond Street Hospital, University College London, London, United Kingdom.
Am J Med Genet A. 2004 Mar 1;125A(2):167-72. doi: 10.1002/ajmg.a.20343.
Angelman syndrome (AS) is an imprinted neurobehavioral disorder characterized by mental retardation, absent speech, excessive laughter, seizures, ataxia, and a characteristic EEG pattern. Classical lesions, including deletion, paternal disomy, or epigenetic mutation, are confirmatory of AS diagnoses in 80% of cases. Loss-of-function mutations of the UBE3A gene have been identified in approximately 8% of AS cases, failing to account for the remaining patient population, and there appears to be a higher prevalence of mutations in familial than sporadic cases. We screened UBE3A in 45 index cases of AS without obvious 15q11-13 abnormalities. Pathological mutations were identified in 3/6 (50%) familial and 4/39 (>10%) sporadic cases. By combining our data with those of the literature, we demonstrate statistically that the frequency of UBE3A mutations is significantly higher in the familial than sporadic subsets of AS. This indicates that an independent molecular mechanism or 'phenocopy' exists for the sporadic group. Rett syndrome (RS), caused by mutations of the MECP2 gene, and patients with deletions of 22q13.3 --> qter, have overlapping clinical features with AS. We screened 24 of the sporadic AS cases without detectable UBE3A mutations for mutations of MECP2, but found none. A separate cohort of 43 atypical patients with features common to AS and RS, in whom 15q11-13 lesions and 22q13.3 --> qter deletion had been ruled out, were also screened for MECP2 mutations. One male patient was mosaic for a frameshift mutation of this gene (previously reported). While MECP2 mutations can cause a phenotype reminiscent of AS in rare cases, they fail to account for the excess of sporadic patients with a definitive clinical diagnosis of AS.
安吉尔曼综合征(AS)是一种印记神经行为障碍,其特征为智力迟钝、无语言能力、过度发笑、癫痫发作、共济失调以及特征性脑电图模式。典型病变,包括缺失、父源二体或表观遗传突变,在80%的病例中可确诊为AS。UBE3A基因功能丧失突变在约8%的AS病例中被发现,但无法解释其余患者群体,并且家族性病例中的突变患病率似乎高于散发性病例。我们对45例无明显15q11 - 13异常的AS索引病例进行了UBE3A筛查。在3/6(50%)的家族性病例和4/39(>10%)的散发性病例中发现了病理性突变。通过将我们的数据与文献数据相结合,我们从统计学上证明,UBE3A突变频率在AS的家族性亚组中显著高于散发性亚组。这表明散发性群体存在独立的分子机制或“拟表型”。由MECP2基因突变引起的雷特综合征(RS)以及22q13.3→qter缺失的患者与AS有重叠的临床特征。我们对24例未检测到UBE3A突变的散发性AS病例进行了MECP2突变筛查,但未发现突变。另外一组43例具有AS和RS共同特征的非典型患者,已排除15q11 - 13病变和22q13.3→qter缺失,也进行了MECP2突变筛查。一名男性患者为此基因的移码突变嵌合体(先前已报道)。虽然MECP2突变在罕见情况下可导致类似AS的表型,但它们无法解释明确临床诊断为AS的散发性患者过多的情况。